课题基金 / 基金详情

Cardioprotective Effects of Dapagliflozin and Exenatide

Cardioprotective Effects of Dapagliflozin and Exenatide
达格列净和艾塞那肽的心脏保护作用
批准号:
367395
负责人:
Zarrin Khat Dorrin
金额:
$1.27万
依托单位:
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-12-01 至 2017-12-01

项目摘要

项目成果

Zarrin Khat Dorrin的其他基金

相似基金

相关文献

中文摘要
翻译
缺血性心血管疾病(CVD)影响着世界上很大一部分人口。2型糖尿病(T2D)患者发生主要不良心血管事件(MACE)的风险特别高,其中CVD是其发病的主要原因
英文摘要
Ischemic cardiovascular disease (CVD) affects a high proportion of the world population. Subjects with type-2 diabetes (T2D) are at particularly high risk of major adverse cardiovascular events (MACE), with CVD representing their leading cause of morbidit
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
  • 批准号:
    404134
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $7.65万
  • 财政年份:
    2018
  • 负责人:
    Zarrin Khat Dorrin
  • 依托单位:
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
  • 批准号:
    396625
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $10.93万
  • 财政年份:
    2018
  • 负责人:
    Zarrin Khat Dorrin
  • 依托单位:
海外基金